Related Experiment Video
Updated: Jul 28, 2026
Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Medical and revascularization management in acute coronary syndrome in renal patients
1Brown University School of Medicine and the Coronary Care Unit, The Miriam Hospital, Providence, RI, USA.
Insights
Managing coronary artery disease in patients with renal impairment is challenging due to diagnostic difficulties and complex treatment needs. Further research is crucial for optimal patient outcomes.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Coronary artery disease (CAD) is highly prevalent in patients with renal impairment.
- These patients often present with asymptomatic cardiac ischemia and atypical diagnostic markers.
- Clinical trials frequently exclude renal impairment subgroups, limiting evidence-based management guidelines.
Purpose of the Study:
- To highlight the diagnostic and management complexities of CAD in patients with renal impairment.
- To review current treatment strategies for acute coronary syndromes in this population.
- To identify gaps in knowledge regarding optimal therapeutic approaches.
Main Methods:
- Review of existing literature on CAD management in renal impairment.
- Analysis of challenges in diagnosing cardiac ischemia in this patient group.
- Discussion of pharmacological and interventional treatment options.
Main Results:
- Thrombolytics are underutilized in acute myocardial infarction.
- Low-molecular weight heparin requires cautious use due to bleeding risk.
- Standard medications like aspirin and metoprolol can be used, but glycoprotein IIb/IIIa inhibitors may need dose adjustment.
- Revascularization via percutaneous coronary intervention or coronary artery bypass grafting is an option, but risks versus benefits are undetermined.
Conclusions:
- Management of CAD in renal impairment is complex, requiring careful consideration of diagnostic limitations and treatment risks.
- Evidence-based guidelines for this population are scarce, necessitating cautious application of existing therapies.
- Further clinical trials are essential to determine optimal revascularization strategies and long-term prognosis.
Abstract:
Despite the high incidence of coronary artery disease in patients with renal impairment, its diagnosis and management remains difficult. The treatment of acute coronary syndrome in this particular group of patients is more complex than in patients with normal renal function. They have a high prevalence of asymptomatic cardiac ischemia. Abnormal baseline electrocardiogram (ECG) findings and nonspecific elevation of cardiac enzymes may be present. Studies are lacking regarding their management mainly because they have been excluded or were not studied as a subgroup in the clinical trials. Thrombolytics are underused during acute myocardial infarction. Heparin, mainly low-molecular weight heparin, for unstable angina and non-Q wave myocardial infarction, should be used with caution because the higher risk for bleeding. Other medications, such as aspirin, metoprolol, and nitroglycerin should be used as in the general population. The newer platelet glycoprotein IIb/IIIa inhibitors may need renal dose adjustment. Revascularization should be pursued if necessary by percutaneous coronary intervention or coronary artery bypass grafting. However, the prognosis and risk of revascularization versus medical therapy have not been determined yet.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:20Acute Kidney Injury V: Interprofessional Care
01:22Acute Kidney Injury VI: Nursing Management
01:28Chronic Kidney Disease III: Interprofessional Care